CDC's ACIP Unanimously Votes To Add Merck And Sanofi's Pediatric Hexavalent Combination Vaccine To Preferential Recommendation For Preventing Invasive Hib Disease In American Indian And Alaska Native Infants; Merck Says Provisional Recommendation Will Be Official Once Reviewed And Finalized By CDC Director And Department Of Health And Human Services
Portfolio Pulse from Benzinga Newsdesk
The CDC's Advisory Committee on Immunization Practices (ACIP) has unanimously voted to add Merck and Sanofi's pediatric hexavalent combination vaccine to the preferential recommendation list for preventing invasive Hib disease in American Indian and Alaska Native infants. The recommendation will become official once reviewed and finalized by the CDC Director and the Department of Health and Human Services.
June 27, 2024 | 7:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's pediatric hexavalent combination vaccine has been added to the CDC's preferential recommendation list for preventing invasive Hib disease in American Indian and Alaska Native infants. The recommendation is pending final approval.
The unanimous vote by the CDC's ACIP to add Merck's vaccine to the preferential recommendation list is a positive development. Once finalized, this could lead to increased adoption and sales of the vaccine, positively impacting Merck's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi's pediatric hexavalent combination vaccine has been added to the CDC's preferential recommendation list for preventing invasive Hib disease in American Indian and Alaska Native infants. The recommendation is pending final approval.
The unanimous vote by the CDC's ACIP to add Sanofi's vaccine to the preferential recommendation list is a positive development. Once finalized, this could lead to increased adoption and sales of the vaccine, positively impacting Sanofi's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100